Tumor metabolic crosstalk and immunotherapy / Diafonía metabólica tumoral e inmunoterapia
Clin. transl. oncol. (Print)
; 26(4): 797-807, Abr. 2024. ilus
Article
in En
| IBECS
| ID: ibc-VR-44
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Tumor cells must resist the host's immune system while maintaining growth under harsh conditions of acidity and hypoxia, which indicates that tumors are more robust than normal tissue. Immunotherapeutic agents have little effect on solid tumors, mostly because of the tumor density and the difficulty of penetrating deeply into the tissue to achieve the theoretical therapeutic effect. Various therapeutic strategies targeting the tumor microenvironment (TME) have been developed. Immunometabolic disorders play a dominant role in treatment resistance at both the TME and host levels. Understanding immunometabolic factors and their treatment potential may be a way forward for tumor immunotherapy. Here, we summarize the metabolism of substances that affect tumor progression, the crosstalk between the TME and immunosuppression, and some potential tumor-site targets. We also summarize the progress and challenges of tumor immunotherapy.(AU)
Search on Google
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Public Health
/
Health Personnel
/
Knee Injuries
/
Pain, Postoperative
/
Palliative Care
/
Pediatrics
/
Pneumonia, Mycoplasma
/
Postoperative Care
/
Postoperative Period
/
Drug Prescriptions
Type of study:
Guideline
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Determinantes_sociais_saude
/
Patient_preference
Limits:
Humans
/
Female
/
Male
/
Aged
/
Adolescent
/
Animals
/
Newborn
/
Pregnancy
Country/Region as subject:
Europa
/
America do sul
/
Brasil
/
Caribe ingles
/
Grenada
Language:
Es
/
En
Journal:
An. pediatr. (2003. Ed. impr.)
/
An. sist. sanit. Navar
/
Asclepio
/
Aten. prim. (Barc., Ed. impr.)
/
Clin. transl. oncol. (Print)
/
Metas enferm
/
Nutr. hosp
/
Psicothema (Oviedo)
/
Rehabilitación (Madr., Ed. impr.)
/
Rev. Soc. Andal. Traumatol. Ortop. (Ed. impr.)
Year:
2023
/
2022
/
2021
/
2024
Document type:
Article